Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8935 results

  1. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  2. Bictegravir–lenacapavir for treating HIV-1 [ID6744]

    Awaiting development Reference number: GID-TA11970 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [TSID12351]

    Awaiting development Reference number: GID-TA11972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [TSID12349]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [TSID12353]

    Awaiting development Reference number: GID-TA11974 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [TSID12350]

    Awaiting development Reference number: GID-TA11975 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [TSID12354]

    Awaiting development Reference number: GID-TA11976 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [TSID12358]

    Awaiting development Reference number: GID-TA11977 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ravulizumab for treating primary IgA nephropathy [ID6703]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  14. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

    Technology appraisal guidance
    In development

  15. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development